Article

Delineation of signals required for thymocyte positive selection.

Michael Heidelberger Division of Immunology, Department of Pathology and New York University Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
The Journal of Immunology (Impact Factor: 5.52). 12/2004; 173(9):5517-23. DOI: 10.4049/jimmunol.173.9.5517
Source: PubMed

ABSTRACT Peptide/MHC complexes capable of inducing positive selection in mouse fetal thymic organ cultures fail to do so in suspension culture. Furthermore, this type of culture does not promote initial stages of differentiation, such as coreceptor down-modulation, unless peptides used for stimulation have (at least) weak agonist activity. We show in this study that signals provided in suspension culture by nonagonist peptide/MHC complexes on the surface of macrophages, even though apparently silent, are sufficient to promote complete phenotypic differentiation when CD4+CD8+ thymocytes are subsequently placed in a proper anatomical setting. Furthermore, the synergistic actions of suboptimal concentrations of phorbol esters and nonagonist peptide/MHC complexes can make the initial stages of positive selection visible, without converting maturation into negative selection. Thus, the correlation between efficiency of positive selection and the degree of coreceptor down-modulation on CD4+CD8+ thymocytes is not linear. Furthermore, these results suggest that the unique role of thymic stromal cells in positive selection is related not to presentation of self-peptide/MHC complexes, but most likely to another ligand.

0 Bookmarks
 · 
77 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the recent increase in the approval and use of biotherapeutics in clinical practice, management of the development of anti-drug antibodies (ADA) has become a key issue for effective long-term use of these drugs. In most instances, the clinical benefit derived from the use of the therapeutics outweighs the risk of developing ADA. In rare instances, however, safety issues accompany development of ADA. Although it is unclear why certain individuals generate an immune response while others tolerate the drug, growing experience from the clinic has facilitated a better appreciation of many patient-, disease- and product-related factors that contribute to immunogenicity. Furthermore, improvements in protein production, purification and delivery methods along with use of humanized or fully human recombinant proteins have helped to reduce the rates of immunogenicity considerably. This document provides an overview of the scientific reasons for developing an immunogenic response, factors that contribute to the immunogenicity of biotherapeutics, clinical impact of immunogenicity and general strategies used to manage this risk.
    Journal of Immunotoxicology 10/2006; 3(3):151-6. · 1.57 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thesis (Ph. D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Microbiology and Immunology, 2007. CD4 T cells constitute a vital subset of T lymphocytes that are essential in regulating immune responses to pathogenic organisms as well as mediating autoimmune diseases. CD4 T cell responses to complex antigens display restricted antigen specificity, with only a few antigen-derived peptides eliciting responses, a phenomenon referred to as immunodominance. Our work using inbred strains of mice and numerous foreign antigens has revealed that within CD4 T cell responses there is a generalized isotype bias, with the majority of T cells responding to peptides presented by the I-A isotype, rather than the I-E class II molecule. Therefore, we undertook a series of experiments to identify specific factors potentially influencing the selectivity of CD4 T cell responses; the CD4 coreceptor and the MHC cofactor DM. It is well established that CD4 binding to MHC enhances the capability of thymocytes and peripheral T cells to respond to presented peptides, both by stabilizing the T cell receptor and peptide/MHC interaction, and by recruiting the signaling molecule p56lck to the T cell receptor. However, the binding of the CD4 coreceptor to the different class II isotypes may be disproportionate, a possibility supported by the location of polymorphisms within the CD4 binding domain. Therefore, using MHC class II molecules with modified CD4 binding sites, as well as mice with disrupted CD4/MHC interactions, we evaluated the importance of the CD4 interaction with the different class II isotypes during antigen recognition. This type of analysis revealed that although there are disparities in the CD4 contribution to T cell activation between T cells restricted to I-A and I-E, this factor alone does not account for the observed biases in peripheral immunodominant CD4 T cell responses. The MHC-encoded cofactor DM, catalyzes endosomal loading of peptides onto MHC class II molecules. Although there is good evidence from in vitro experiments that DM acts to selectively edit the repertoire of class II:peptide complexes presented by antigen presenting cells, the consequence of DM expression in vivo, or a predictive pattern of DM activity in the specificity of CD4 T cell responses has remained unresolved. To characterize DM function in vivo we utilized wild type (WT) or DM-deficient (DM-/-) mice of the H-2d MHC haplotype and tested the hypothesis that DM promotes narrowing of the repertoire of class II:peptide complexes displayed by APC, leading to a correspondingly selective CD4 T cell response. Surprisingly, our results indicated that DM-/- mice do not exhibit a broadened CD4 T cell response relative to WT mice, but rather shift their immunodominance pattern to new peptides, a pattern associated with a change in class II isotype-restriction. Specifically, we found that while CD4 T cell responses in WT mice were primarily restricted to the I-A class II molecule, DM-/- mice predominantly recognize peptides in the context of I-E. The observed shift in isotype-restriction appeared to be due in part to a modification in the peripheral CD4 T cell repertoire available for peptide recognition.
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD47 is a ubiquitously expressed molecule which has been attributed a role in many cellular processes. Its role in preventing cellular phagocytosis has defined CD47 as an obligatory self-molecule providing a 'don't-eat-me-signal'. Additionally, CD47-CD172a interactions are important for cellular trafficking. Yet, the contribution of CD47 to T cell stimulation remains controversial, acting sometimes as a co-stimulator and sometimes as an inhibitor of TCR signalling or peripheral T cell responses. Most of the experiments leading to this controversy have been carried in in vitro systems. Moreover, the role of CD47 on thymocyte differentiation, which precisely relies on TCR signal strength, has not been evaluated. Here, we examine the in vivo role of CD47 in T cell differentiation using CD47-deficient mice. We find that, in the absence of CD47, thymocyte positive and negative selection processes are not altered. Indeed, our data demonstrate that the absence of CD47 does not influence the strength of TCR signalling in thymocytes. Furthermore, in agreement with a role for CD47-CD172a interactions in CD172a(+) dendritic cell migration, we report a reduced proportion of thymic dendritic cells expressing CD172a in CD47-deficient mice. As the total proportion of dendritic cells is maintained, this creates an imbalance in the proportion of CD172a(+) and CD172a(low) dendritic cells in the thymus. Together, these data indicate that the altered proportion of thymic dendritic cell subsets does not have a primordial influence on thymic selection processes.
    International Immunology 02/2009; 21(2):167-77. · 3.14 Impact Factor

Full-text (2 Sources)

Download
4 Downloads
Available from
Jun 4, 2014